Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

• ClinicalTrials.gov Identifier: NCT03680131
• Recruitment Status: Active, not recruiting
• First Posted: September 21, 2018
• Last Update Posted: September 13, 2022
• Sponsor: Edesa Biotech Inc.
• Collaborator: JSS Medical Research Inc.
• Information provided by (Responsible Party): Edesa Biotech Inc.

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD).

The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.

Condition or disease	Intervention/treatment	Phase
Allergic Contact Dermatitis	Drug: EB01 Cream Placebo; Drug: EB01 Cream 0.2%; Drug: EB01 Cream 1.0%; Drug: EB01 Cream 2.0%	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 126 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis
• Actual Study Start Date: October 15, 2019
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: March 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: EB01 Cream Placebo; EB01 Cream containing 0% EB01 w/w applied BID	Drug: EB01 Cream Placebo; Vehicle Cream containing 0% EB w/w applied BID
Experimental: EB01 Cream 0.2%; EB01 Cream containing 0.2% EB01 w/w applied BID	Drug: EB01 Cream 0.2%; EB01 Cream containing 0.2% EB01 w/w applied BID
Experimental: EB01 Cream 1.0%; EB01 Cream containing 1.0% EB01 w/w applied BID	Drug: EB01 Cream 1.0%; EB01 Cream containing 1.0% EB01 w/w applied BID
Experimental: EB01 Cream 2.0%; EB01 Cream containing 2.0% EB01 w/w applied BID	Drug: EB01 Cream 2.0%; EB01 Cream containing 2.0% EB01 w/w applied BID

Outcome Measures

Primary Outcome Measures :

1. Mean percent change from baseline in the Contact Dermatitis Severity Index (CDSI) [ Time Frame: Day 29 ]

Secondary Outcome Measures :

1. Mean percent change from baseline in CDSI [ Time Frame: Days 15, 59, 89, and 119 ]
2. Proportion of subjects achieving at least a 2-grade reduction from baseline to clear (0) or almost clear (1) in Investigator's Static Global Assessment (ISGA) [ Time Frame: Days 15, 29, 59, 89, and 119 ]
3. Proportion of patients achieving at least a 2-point reduction from peak pruritis Numerical Rating Scale (NRS) score from Baseline [ Time Frame: Days 15, 29, 59, 89, and 119 ]
4. Proportion of patients achieving at least a 4-point reduction from peak pruritis Numerical Rating Scale (NRS) score from Baseline [ Time Frame: Days 15, 29, 59, 89, and 119 ]
5. Mean percent change from baseline in Body Surface Area (BSA) affected with chronic allergic contact dermatitis [ Time Frame: Days 15, 29, 59, 89, and 119 ]
6. Change from baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: Days 15, 29, 59, 89, and 119 ]

Other Outcome Measures:

1. Treatment-emergent adverse events (TEAEs) [ Time Frame: To Day 36, and for open-label extension to Day 119 ]
   Number of events
2. Tolerability assessed using a numerical rating scale [ Time Frame: To Day 36, and for open-label extension to Day 119 ]
   Tolerability will be assessed using a numerical rating scale from 0 to 10, and will evaluate skin burning, stinging and pruritus during treatment

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

INCLUSION CRITERIA

All subjects:

1. Men and women ≥ 18 years old, inclusive, at the time of consent.

2. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: the subject must agree to use an effective contraceptive method from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application. Effective contraceptive methods include hormonal contraceptives (combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s), tubal ligation, or a barrier method of contraception (male condom, female condom, cervical cap, diaphragm, contraceptive sponge) in conjunction with spermicide.

   Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks before Day 1.

   Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse throughout the study. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

   Note: A woman of nonchildbearing potential is as follows:

   1. Woman who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);
   2. Woman who has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels).
3. For men involved in any sexual intercourse that could lead to pregnancy, subject must agree to use one of the effective contraceptive methods listed in Inclusion Criterion #2 from Day 1 until at least 4 weeks after the last study product application. If the female partner of a male subject use any of the hormonal contraceptive methods listed above, this contraceptive method must be used by the female partner from at least 4 weeks before Day 1 until at least 4 weeks after the last study product application.
4. Female of childbearing potential has had a negative pregnancy test at screening visit .
5. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
6. Subjects must be willing to comply with all study procedures and must be available for the duration of the study.

HV only:

1. Subject is in good general health, according to the investigator's judgment based on medical history and physical examination/laboratory/ECG/vital signs assessments.

Subjects with allergic contact dermatitis only:

1. Subject has at least 3-month history of allergic contact dermatitis (information obtained from medical chart or subject's physician, or directly from the subject).

2. Subject has moderate to severe chronic allergic contact dermatitis at Day 1, defined by either one of the following:

   • CDSI score ≥ 7
   • CDSI score of severe (3) in ≥ 2 of the 5 assessed symptoms (Fissures, Scaling Redness, Pruritus, Dryness)
3. Subject has allergic contact dermatitis covering between 0.5% to 10% of the total BSA at Day 1.
4. Subject has an ISGA ≥ 3 at Day 1.

5. The subject has had a positive patch test ("+", "++" or "+++" reaction) to an allergen that is suspected to be involved in the current allergic contact dermatitis in the past 5 years (obtain written documentation of patch test result if possible).

   Alternatively, the Subject agrees to undergo patch testing during the screening period (patch testing needs to be initiated but not completed prior to Day 1). Guidelines for patch test interpretation are provided in Appendix 2. The measure of the degree of the reaction will be determined on the basis of the reading 2 and 3-4 days post application.

6. Subject agrees to only apply personal care products (i.e. makeup and eyeshadow) that do not contain their allergen(s) on lesions only after applying the IP.
7. Subject agrees not to apply any personal care products on allergic contact dermatitis lesions prior to site visits.

Subjects with allergic contact dermatitis in the Open Label Extension:

1. Subject has completed the main study.

EXCLUSION CRITERIA

All subjects:

1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
2. Current or recurrent disease, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only), that could affect the action, absorption, or disposition of the study drug, or clinical or laboratory assessments.
3. Subject has a history of skin disease or presence of skin condition, other than allergic contact dermatitis (applicable to subject with allergic contact dermatitis only), that in the opinion of the investigator, would interfere with the study assessments.
4. Subject is known to have immune deficiency or is immunocompromised.
5. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
6. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
7. Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
8. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
9. Subject has used systemic treatments (other than biologics) that could affect allergic contact dermatitis (applicable to subjects with allergic contact dermatitis only) or is known to cause cutaneous irritation or sensitization reactions less than 2 weeks prior to Day 1 (e.g., oral/injectable corticosteroids, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide [hydroxyurea], azathioprine) Note: Intranasal corticosteroids and inhaled corticosteroids for stable medical conditions are allowed. Eye drops containing corticosteroids are allowed.
10. Use of any prescription or over-the-counter (OTC) medication that, in the opinion of the Principal Investigator, could affect (improve or worsen) the allergic contact dermatitis condition or is known to cause cutaneous irritation or sensitization reactions.
11. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
12. Subject is currently receiving a nonbiological investigational product or device or has received one within 2 weeks prior to Day 1.
13. Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 2 weeks prior to Day 1.
14. Subject had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 2 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products and protective apparel are recommended when exposure cannot be avoided. If sunscreen is applied to ACD lesions, it should be applied after the IP.
15. Subject has a known hypersensitivity to EB01 or its excipients.
16. Subject has uncontrolled diabetes.
17. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.

HV only:

1. Subject has history of recurrent chronic or presence of allergic contact dermatitis.
2. Subject has used any medicated topical product on the face within 2 weeks prior to Day 1.

Subjects with allergic contact dermatitis only:

1. Subjects with active atopic dermatitis lesions overlapping with allergic contact dermatitis lesions at Day 1.
2. Subject has clinically infected allergic contact dermatitis lesions (bacterial, viral, or fungal).
3. Subject has allergic contact dermatitis on lips or mucous membranes only.
4. Subject has used dupilumab within 12 weeks prior to Day 1.
5. Subject has used doxepin within 1 week prior to Day 1.
6. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
7. Subject has used topical products containing urea within 1 week prior to Day 1.
8. Subject has used systemic antibiotics within 1 weeks or topical antibiotics on lesions of allergic contact dermatitis within 1 week prior to Day 1.
9. Subject has used any topical medicated treatment for allergic contact dermatitis within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole and any other topical phosphodiesterase-4 inhibitor, calcineurin inhibitors, tars, bleach, antimicrobials and medical devices.

Contacts and Locations

Locations

United States, California

Ark Clinical Research

Long Beach, California, United States, 90806

United States, District of Columbia

Foxhall Dermatology

Washington, District of Columbia, United States, 20016

United States, Florida

Gold Coast Dermatology

Delray Beach, Florida, United States, 33446

Miami Dade Medical Research Institute, LLC

Miami, Florida, United States, 33176

United States, Indiana

The Dermatology Centre of Indiana

Plainfield, Indiana, United States, 46168

United States, Kentucky

Forefront Dermatology

Louisville, Kentucky, United States, 40202

United States, Louisiana

The Dermatology Clinic

Baton Rouge, Louisiana, United States, 70808

United States, Minnesota

Associated Skin Care Specialists

Fridley, Minnesota, United States, 55432

United States, New York

JUVA Skin & Laser Center

New York, New York, United States, 10022

United States, North Carolina

UNC Dermatology and Skin Cancer Center

Chapel Hill, North Carolina, United States, 27516

United States, Ohio

Bexly Dermatology

Bexley, Ohio, United States, 43209

United States, West Virginia

West Virginia Research Institute

Morgantown, West Virginia, United States, 26505

Canada, Ontario

Lynderm Research Inc.

Markham, Ontario, Canada, L3P 1X2

Sponsors and Collaborators

Edesa Biotech Inc.

JSS Medical Research Inc.

More Information

• Responsible Party: Edesa Biotech Inc.
• ClinicalTrials.gov Identifier: NCT03680131
• Other Study ID Numbers: EB01-01-2018
• First Posted: September 21, 2018
• Last Update Posted: September 13, 2022
• Last Verified: September 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Dermatitis; Dermatitis, Contact; Dermatitis, Allergic Contact; Skin Diseases; Skin Diseases, Eczematous; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases